Showing 4081-4090 of 8129 results for "".
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- Rademikibart 'Could Be Incredibly Important for Type 2'https://practicaldermatology.com/news/rademikibart-could-be-incredibly-important-type-2/2468551/A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference. Dr. Bunick showed
- Starton Secures New Patent for Transdermal Lenalidomide Deliveryhttps://practicaldermatology.com/news/starton-secures-new-patent-transdermal-lenalidomide-delivery/2468506/Starton Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its STAR-LLD transdermal drug delivery patent application, providing potential extended patent protection through 2040. According to a press release, the development broad
- ECZTEND: Tralokinumab-ldrm Achieves Lasting Efficacy in AD Patientshttps://practicaldermatology.com/news/ecztend-tralokinumab-ldrm-achieves-lasting-efficacy-ad-patients/2468493/Final results presented at Fall Clinical 2024 from the ECZTEND study confirmed long-term safety and efficacy of tralokinumab-ldrm in adolescents and adults with moderate-to-severe atopic dermatitis (AD). The open-label, single-arm trial included 1,672 participants who transitioned from nin
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p
- Verrica To Share Phase 2 Results for VP-315 in BCC Treatment at Fall Clinicalhttps://practicaldermatology.com/news/verrica-share-phase-2-results-vp-315-bcc-treatment-fall-clinical/2468470/Verrica Pharmaceuticals announced today that two abstracts featuring positive topline results from their phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC) will be presented at the 2024 Fall Clinical Dermatology Conference. The presentations will focus on safety, tole
- Study Backs CP-GEP Tests’ Accuracyhttps://practicaldermatology.com/news/study-backs-cp-gep-tests-accuracy/2468469/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the Society of Me
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<
- World Hair Transplant Repair Day Set for November 11https://practicaldermatology.com/news/world-hair-transplant-repair-day-set-november-11/2468428/The International Society of Hair Restoration Surgery (ISHRS) will host its annual “World Hair Transplant Repair Day” on November 11, part of the ISHRS’s Fight the FIGHT (an acronym for Fight the Fraudulent, Illicit, and Global Hair Transplants) global consumer awareness campaign designed to educ
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter